Portage Biotech Stock (NASDAQ:PRTG), Trade Ideas

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADPT

ADSK

ALXO

ASML

AWIN

CGEM

CHRO

CXAI

DFLI

DXYZ

DYNT

EDBL

EZGO

FNCH

FWRD

HUBC

IBKR

INVO

ISUN

JBHT

LGVN

MSTR

OTRK

PLCE

PRTG

RANI

SAGE

SBFM

SINT

SMXT

SNDL

SPEC

SXTC

TCON

TPET

VIAO

VIRX

VNDA

WISA

Shares of  The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ABTS

ALAB

AMTX

APYX

ARGX

ASST

AVGR

BPTS

CRML

CURI

CZOO

DRCT

FIVE

GOEV

HOUS

INTJ

JOAN

KAVL

LVWR

LXEH

MVLA

NSYS

OCGN

PALT

PGEN

PYXS

SPIR

STEM

TITN

TRML

WLDS

YTEN

Shares of  FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

ACMR

AFIB

ALHC

ALPN

AUGX

BTDR

BYND

CJET

CLSK

CMTL

COIN

CRNX

DCGO

ELVN

ENVB

FUSN

GWAV

HOTH

HUYA

LICY

MARA

MBTC

MNPR

NCMI

PIXY

PRSO

SEEL

SMCI

SOUN

STNE

SWIN

VERB

WORX

ZCAR

ZEPP

Shares of  Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Portage Biotech Inc

&nbsp;Immutep Limited ((ASX: IMM, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) (&ldquo;Immutep&rdquo; or &ldquo;the Company&rdquo;), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) &nbsp;Phase &nbsp;IIb &nbsp;trial &nbsp;evaluating &nbsp;eftilagimod &nbsp;alpha &nbsp;(efti) in combination with MSD&rsquo;s anti-PD-1 &nbsp;therapy KEYTRUDA&reg; &nbsp;(pembrolizumab) &nbsp;as &nbsp;first-line treatment of &nbsp;recurrent/metastatic &nbsp;head &nbsp;and &nbsp;neck &nbsp;squamous &nbsp;cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

IMMP

Immutep Announced Tuesday, Data  From Efti In  Combination  With Keytruda In  First  Line Head  And  Neck  Squamous  Cell  Carcinoma Patients Who Do Not Express PD-L1 Shows A Preliminary 26.9% Response Rate, The Primary Endpoint Of The Study

Pivotal Research analyst Jeffrey Wlodarczak upgrades Sirius XM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) from Hold to Buy and lowers the price target from $5.05 to $4.9.

Upgrades

Price Target

Analyst Ratings

SIRI

Pivotal Research Upgrades Sirius XM Holdings to Buy, Lowers Price Target to $4.9

<a href="https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies" title="https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies">https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babies</a>

Biotech

Large Cap

Health Care

General

Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety

Elon Musk has escalated his conflict with the Australian government, advocating for the incarceration of a senator and voicing criticism of Australia&#8217;s gun laws. This follows a court directive to remove a violent video from his social media platform, X.
What Happened: On Tuesday, an X user posted a clip of Australian Sen. Jacqui Lambie who deleted her X account and encouraged other politicians to follow suit. Lambie criticized Musk for his lack of social conscience and suggested he should be jailed.
"…quite frankly, the power that that man has because of that platform that he's on, it's got to stop. It has absolutely got to stop. But leaving that out for our kids to see, for people that were family and friends out there and just letting that run on there, once again, that bloke has no conscience. He's an absolute friggin disgrace, and there's nothing else to say about Elon Musk," Lambie said. 
Musk responded to the post, saying, &#8220;Absolutely. She is an enemy of the people of Australia.&#8221;
Musk&#8217;s disagreement with Australian authorities heightened after a federal court demanded his social media platform, X, to temporarily stop displaying a video showing a knife assault on an Assyrian bishop, This order led Musk to accuse Australia&#8217;s leaders of internet censorship.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Absolutely. She is an enemy of the people of Australia.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1782823597381414933?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/24/04/38357333/elon-musk-reacts-to-tucker-carlson-saying-theres-ton-of-evidence-that-aliens-live-among-us-with-6000?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Tucker Carlson Saying There&#8217;s &#8216;Ton Of Evidence&#8217; That Aliens Live Among Us: &#8216;With 6000 Satellites Orbiting Earth, I Think I Would Know&#8217;</a>
Why It Matters: This incident follows a <a href="https://www.benzinga.com/government/23/10/35257873/elon-musks-x-faces-386k-penalty-in-australia-for-dodging-child-abuse-probe">penalty of $386,000</a> that was imposed on X by the Australian regulator last year for inadequate compliance with a child abuse prevention investigation.
Musk extended his criticism to Australia&#8217;s 1996 gun buy-back and registration scheme, endorsing a post that alleged the scheme was designed to prevent resistance against its &#8220;fascist government&#8221;.
Australia&#8217;s Home Affairs Minister <a href="https://www.benzinga.com/news/24/04/38368734/elon-musk-hits-back-at-australias-leader-amid-row-over-removal-of-violent-video-from-x-does-the-pm-t">Clare O&#8217;Neill accused social media companies</a> of inciting &#8220;civil division, social unrest&#8221; and criticized Musk for legally defending the right to display alleged terrorist content on his platform. 
A hearing to decide the permanence of the takedown order is scheduled for May 10.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38348301/bitcoin-halving-elon-musks-dogecoin-tweet-solanas-rise-and-more-this-week-in-cryptocurrenc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin Halving, Elon Musk&#8217;s Dogecoin Tweet, Solana&#8217;s Rise And More: This Week In Cryptocurrency</a>
Photo courtesy: Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Social Media

Global

Tech

'Enemy Of People:' Elon Musk Slams Australian Senator After She Calls Tesla CEO 'Absolute Friggin Disgrace'

Pivotal Research analyst Jeffrey Wlodarczak maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $390 to $400.

SPOT

Pivotal Research Maintains Buy on Spotify Technology, Raises Price Target to $400

Needham analyst Joshua Reilly reiterates Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and maintains $400 price target.

Reiteration

AXON

Needham Reiterates Buy on Axon Enterprise, Maintains $400 Price Target

Piper Sandler analyst Brad Milsaps downgrades Independent Bank Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBTX#NASDAQ">IBTX</a>) from Neutral to Underweight and lowers the price target from $48 to $38.

Downgrades

IBTX

Piper Sandler Downgrades Independent Bank Gr to Underweight, Lowers Price Target to $38

Needham analyst Ryan Koontz maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and lowers the price target from $50 to $45.

CALX

Needham Maintains Buy on Calix, Lowers Price Target to $45

Piper Sandler analyst Brian Mullan initiates coverage on Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) with a Neutral rating and announces Price Target of $114.

Initiation

KRUS

Piper Sandler Initiates Coverage On Kura Sushi USA with Neutral Rating, Announces Price Target of $114

Piper Sandler analyst Stephen Scouten upgrades SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) from Neutral to Overweight and raises the price target from $25 to $26.

SMBK

Piper Sandler Upgrades SmartFinancial to Overweight, Raises Price Target to $26

Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and raises the price target from $30 to $33.

DAWN

Needham Maintains Buy on Day One Biopharmaceutical, Raises Price Target to $33

Mizuho analyst James Lee upgrades Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Neutral to Buy and raises the price target from $150 to $200.

ABNB

Mizuho Upgrades Airbnb to Buy, Raises Price Target to $200

Outlook&nbsp;for the&nbsp;Fourth Quarter&nbsp;of the Fiscal Year 2024
New Oriental expects total net revenues in the&nbsp;fourth quarter&nbsp;of the fiscal year 2024 (March 1, 2024&nbsp;to&nbsp;May 31, 2024) to be in the range of&nbsp;US$1,101.5 million&nbsp;to&nbsp;US$1,127.3 million, representing year over year increase in the range of&nbsp;28%&nbsp;to&nbsp;31%.
The projected increase of revenue in our functional currency Renminbi is expected to be in the range of&nbsp;34%&nbsp;to&nbsp;37%&nbsp;for the&nbsp;fourth quarter&nbsp;of the fiscal year 2024.

Guidance

New Oriental Education & Technology Group

New Oriental Education Expects Q4 Revenue of $1.102B-$1.127B Vs $1.099B Est

New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) reported quarterly earnings of $0.63 per share which missed the analyst consensus estimate of $0.79 by 20.25 percent. This is a 12.5 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $1.207 billion which beat the analyst consensus estimate of $1.105 billion by 9.30 percent. This is a 60.09 percent increase over sales of $754.153 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

New Oriental Education Q3 2024 Adj EPS $0.63 Misses $0.79 Estimate, Sales $1.207B Beat $1.105B Estimate

Lloyds Banking Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYG#NYSE">LYG</a>) reported quarterly earnings of $0.22 per share. This is a 98.2 percent increase over earnings of $0.11 per share from the same period last year. The company reported $4.04 billion in sales this quarter. This is a 30.62 percent decrease over sales of $5.82 billion the same period last year.

Lloyds Banking Group Q1 EPS $0.22 Up From $0.11 YoY, Sales $4.04B Down From $5.82B YoY

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) has cut its <a href="https://www.benzinga.com/news/24/04/38136012/apple-vision-pros-immersive-content-library-to-expand-with-a-dinosaur-film-iphone-16-to-further-boos">Vision Pro </a><a href="https://www.benzinga.com/news/24/04/38136012/apple-vision-pros-immersive-content-library-to-expand-with-a-dinosaur-film-iphone-16-to-further-boos">shipments</a> by nearly half due to a significant drop in demand, according to a new report.
What Happened: The Cupertino-based tech giant has revised its Vision Pro shipment estimates to 400,000-450,000 units for 2024, down from the initial 700,000-800,000 units. The changes have forced Apple to reconsider its overall headset strategy, <a href="https://medium.com/@mingchikuo/apple-cuts-2024-2025-vision-pro-shipment-forecasts-unfavorable-to-mr-headset-pancake-and-micro-38796834f930">said</a> analyst Ming-Chi Kuo.
He suggests that the demand for Vision Pro has dropped significantly in the United States, leading Apple to adopt a cautious approach to its international launch. This has prompted Apple to re-evaluate its headset business strategy.
"Apple cut orders before launching Vision Pro in non-US markets, which means that demand in the US market has fallen sharply beyond expectations, making Apple take a conservative view of demand in non-US markets."
Kuo also hinted that Apple might not release a second-generation Vision Pro in 2025, as previously speculated.
See Also: <a href="https://www.benzinga.com/markets/equities/24/04/38345502/elon-musk-reacts-after-nvidia-stock-plunges-10-and-erases-212b-market-cap-rookie-numbers?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts After Nvidia Stock Plunges 10% And Erases $212B Market Cap: &#8216;Rookie Numbers&#8217;</a>
Apple had previously planned to produce approximately 400,000 Vision Pro headsets in 2024. It is possible that Apple increased this target before the Vision Pro&#8217;s release in February, only to now lower it again.
Apple is <a href="https://www.benzinga.com/news/24/03/37862487/apple-planning-to-launch-vision-pro-next-in-these-countries-next-here-is-what-latest-job-postings-re">expected to expand</a> the Vision Pro's availability at the upcoming Worldwide Developers Conference (WWDC) in June.
Why It Matters: The Vision Pro, which <a href="https://www.benzinga.com/news/24/02/37048792/sam-altman-lauds-apple-vision-pro-second-most-impressive-tech-since-the-iphone">launched in February</a>, has been a topic of debate. Privacy expert Albert Fox Cahn criticized it as a &#8220;buggy beta test of a product launch,&#8221; raising concerns about increased surveillance.
Despite this, the headset <a href="https://www.benzinga.com/news/24/02/37048792/sam-altman-lauds-apple-vision-pro-second-most-impressive-tech-since-the-iphone">received praise from industry leaders</a>, with OpenAI co-founder Sam Altman calling it the second most impressive tech since the iPhone.
Price Action: Apple's shares were up 0.23% in premarket trading on Wednesday after closing at $166.82 on Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38381758/jim-cramer-weighs-in-after-iphone-sales-reportedly-plummet-19-in-china-in-q1-anothe">Jim Cramer Weighs In After iPhone Sales Reportedly Plummet 19% In China In Q1: &#8216;Another Dump On Apple iPhone Day&#8217;</a>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Mylo Kaye on Unsplash

Analyst Color

AAPL

Apple In Trouble? Tim Cook Reportedly Cuts Vision Pro Shipment Forecasts By Up To 50%, Analyst Says Demand Has 'Fallen Sharply'

RYAAY

Ryanair CEO Said We Will Continue To Be Boeing's Largest Customer Outside America

Keefe, Bruyette &amp; Woods analyst Ryan Krueger upgrades Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) from Market Perform to Outperform and lowers the price target from $130 to $110.

Keefe, Bruyette & Woods Upgrades Globe Life to Outperform, Lowers Price Target to $110

Ryanair CEO Said Doesn't Make A Lot Of Difference If Boeing Owns Spirit, But Quality Control Needs To Be Improved; We've Been Finding A Lot Of The Production Issues Ourselves, Quality Controls Haven't Been Very Good With Boeing

Ryanair CEO Said It Will Take 12-18 Months For Boeing To Eliminate Backlogs In Deliveries

Portage Biotech GAAP EPS of -$0.29

Opko Health, LifeMD among healthcare movers

Portage Biotech to halt iNKT drug program, cut workforce

Portage Biotech Inc (PRTG) stock is down -82.41% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives PRTG stock a score of  27 out of a possible 100. That rank is  influenced by a short-term technical score of 1. PRTG's rank also i

Should You Sell Portage Biotech Inc (PRTG) Stock Friday?

Portage Biotech Inc (PRTG) stock is down 28.57% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator. Portage Biotech Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PRTG!See Full PRTG ReportWhat is Stock Sentiment?Sentiment is a v

Should You Buy Portage Biotech Inc (PRTG) Stock After it Has Fallen 28.57% in a Week?

Analysts fell to the sidelines weighing in on Harpoon Therapeutics (HARP – Research Report), Portage Biotech Inc (PRTG – Research Report) and Ambrx...

Analysts Offer Insights on Healthcare Companies: Harpoon Therapeutics (HARP), Portage Biotech Inc (PRTG) and Ambrx Biopharma (AMAM)

InvestorsObserver is giving Portage Biotech Inc (PRTG) an Analyst Rating Rank of 5, meaning PRTG is ranked higher by analysts than 5% of stocks. The average price target for PRTG is $7 and analystâ€&#x2122;s rate the stock as a Hold. Wall Street analysts are rating PRTG a Hold today.  Find out what this means to you and get the res

Where Does Wall Street Think Portage Biotech Inc (PRTG) Stock Will Go?